Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | free fatty acid receptor 1 | Starlite/ChEMBL | References |
Homo sapiens | free fatty acid receptor 1 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | metal transporter, putative | 0.0052 | 0.0131 | 0.5 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0027 | 0 | 0.5 |
Brugia malayi | NRAMP-like transporter K11G12.4 | 0.0052 | 0.0131 | 1 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0027 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.0131 | 1 |
Trypanosoma brucei | Alkylated DNA repair protein (alkB homolog), putative | 0.0027 | 0 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.1949 | 1 | 1 |
Schistosoma mansoni | divalent metal transporter DMT1B | 0.0052 | 0.0131 | 1 |
Trypanosoma cruzi | alkylated DNA repair protein, putative | 0.0027 | 0 | 0.5 |
Trypanosoma brucei | 2OG-Fe(II) oxygenase superfamily, putative | 0.0027 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0027 | 0 | 0.5 |
Trypanosoma brucei | 2OG-Fe(II) oxygenase superfamily, putative | 0.0027 | 0 | 0.5 |
Trypanosoma brucei | 2OG-Fe(II) oxygenase superfamily, putative | 0.0027 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0027 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.1949 | 1 | 1 |
Trypanosoma brucei | 2OG-Fe(II) oxygenase superfamily, putative | 0.0027 | 0 | 0.5 |
Toxoplasma gondii | divalent metal transporter, putative | 0.0052 | 0.0131 | 1 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0027 | 0 | 0.5 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0027 | 0 | 0.5 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0027 | 0 | 0.5 |
Echinococcus multilocularis | divalent metal transporter DMT1B | 0.0052 | 0.0131 | 1 |
Schistosoma mansoni | divalent metal transporter DMT1B | 0.0052 | 0.0131 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0027 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.0131 | 1 |
Echinococcus granulosus | divalent metal transporter DMT1B | 0.0052 | 0.0131 | 1 |
Trypanosoma brucei | 2OG-Fe(II) oxygenase superfamily, putative | 0.0027 | 0 | 0.5 |
Plasmodium falciparum | transporter, putative | 0.0052 | 0.0131 | 0.5 |
Onchocerca volvulus | Protein Malvolio homolog | 0.0052 | 0.0131 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0027 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 104 nM | Agonist activity at mouse GPR40 expressed in CHO cells assessed as intracellular calcium mobilization by FLIPR assay | ChEMBL. | 21514824 |
EC50 (functional) | = 113 nM | Agonist activity at human GPR40 expressed in CHO cells assessed as intracellular calcium mobilization by FLIPR assay | ChEMBL. | 21514824 |
EC50 (functional) | = 306 nM | Agonist activity at human GPR40 expressed in HEK293 cells assessed as [3H]IP3 production in presence of 10% human serum | ChEMBL. | 21514824 |
EC50 (functional) | = 349 nM | Agonist activity at human GPR40 expressed in HEK293 cells assessed as [3H]IP3 production in presence of 0.4% serum albumin | ChEMBL. | 21514824 |
IC50 (binding) | = 49 nM | Inhibition of human GPR40 expressed in CHO cells by SPA based binding assay | ChEMBL. | 21514824 |
IC50 (binding) | = 25 uM | Inhibition of human ERG | ChEMBL. | 21514824 |
IC50 (binding) | = 25.6 uM | Inhibition of Cav1.2 calcium channel | ChEMBL. | 21514824 |
IC50 (ADMET) | = 28 uM | Inhibition of CYP2C9 | ChEMBL. | 21514824 |
IC50 (ADMET) | > 50 uM | Inhibition of CYP2D6 | ChEMBL. | 21514824 |
IC50 (ADMET) | > 50 uM | Inhibition of CYP3A4 | ChEMBL. | 21514824 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.